ABOUT US OUR SCIENCE OUR PIPELINE OUR MEDICINES MINORITY INVESTMENTS INVESTORS SEARCH NEWSROOM SCIENCE CENTER - CHISHIKI CAREERS CONTACT Press releases LATEST 2020 2019 2018 ARCHIVE Nov 22, 2021 Sosei Heptares to Host Investor Briefing to Discuss Newly Announced Collaboration with Neurocrine Biosciences READ MORE... Nov 22, 2021 Presentation and Webcast - Sosei Heptares and Neurocrine Biosciences Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders READ MORE... Nov 22, 2021 Sosei Heptares and Neurocrine Biosciences Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders READ MORE... Nov 16, 2021 Sosei Heptares to present at the Jefferies London Healthcare Conference 2021 READ MORE... Nov 12, 2021 Sosei Heptares Notes that its Partnered Adenosine A2a Antagonist Imaradenant (AZD4635) has been Removed from AstraZeneca’s Clinical Pipeline READ MORE... Nov 11, 2021 Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021 READ MORE... Aug 12, 2021 Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021 READ MORE... Jul 21, 2021 Sosei Heptares Webinar Presentation for Second Quarter FY2021 Financial Results READ MORE... Jul 7, 2021 Sosei Announces Determination of the Issuance Terms for its Convertible Bonds READ MORE... Jul 7, 2021 Sosei Announces Issuance of Convertible Bonds and Buyback of Existing Convertible Bonds READ MORE... Jul 6, 2021 Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration READ MORE... Jun 23, 2021 Sosei Heptares Initiates Phase 1 Trial with Novel Small-Molecule CGRP Antagonist under Collaboration with Biohaven READ MORE... Jun 4, 2021 Notice Regarding Determination of Payment Amount and Other Matters of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan READ MORE... May 25, 2021 Sosei Heptares to present at UBS Global Healthcare Virtual Conference 2021 READ MORE... May 19, 2021 Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials READ MORE... May 12, 2021 Sosei Heptares notes PeptiDream announced achievement of milestone in PAR2 peptide antagonist collaboration READ MORE... May 12, 2021 Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021 READ MORE... Apr 21, 2021 Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan READ MORE... Apr 1, 2021 Notice of Issuance of New Shares Under Restricted Stock Unit (RSU) Plan READ MORE... Mar 24, 2021 Annual Securities Report (Year ended 31 December 2020) READ MORE... Mar 24, 2021 Sosei Heptares Confirms Board and Executive Management Appointments at 31st Annual Shareholders’ Meeting READ MORE... Mar 11, 2021 Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals READ MORE... Mar 2, 2021 Information Disclosure on the Internet Regarding the Notice of the 31st ordinary General meeting of Shareholders READ MORE... Mar 2, 2021 Notice of the 31st Ordinary General Meeting of Shareholders READ MORE... Feb 16, 2021 Sosei Heptares spin-off Company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals READ MORE... Feb 15, 2021 FY2020 Financial Results Conference Call READ MORE... Feb 12, 2021 Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020 READ MORE... Feb 1, 2021 Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences READ MORE... Jan 12, 2021 Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target READ MORE... Jan 11, 2021 Sosei Heptares to present at 39th Annual J.P. Morgan Healthcare Conference READ MORE... Jan 5, 2021 Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs READ MORE... TERMS OF USE PRIVACY NOTICE COOKIE POLICY MODERN SLAVERY STATEMENT © Sosei Group Corporation 2021 Sosei Heptares is the corporate brand of Sosei Group Corporation (TSE:4565) External Link Icon I Do Not Accept Essential Cookies Essential cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences. Analytics/Performance Cookies Analytical cookies help us to improve our website by collecting and reporting information on its usage. Analytics/Performance Cookies On Off Cookie Control